首页> 外文期刊>International Journal of Epidemiology: Official Journal of the International Epidemiological Association >A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study.
【24h】

A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study.

机译:根据Glostrup人口研究和Framingham心脏研究的数据,对冠心病死亡率的风险得分进行交叉验证。

获取原文
获取原文并翻译 | 示例
           

摘要

Background Due to marked regional differences in the incidence of coronary heart disease (CHD) in Europe, the recommendation by the European Society of Cardiology to use the Coronary Risk Chart based on data from the Framingham Heart Study, could be questioned. Methods Data from two population studies (The Glostrup Population Studies, n = 4757, the Framingham Heart Study, n = 2562) were used to examine three different levels of cross-validation. The first level of examination was whether a risk-score developed from one sample adequately ordered the risk of participants in the other sample, using the Area Under a Receiver Operating Characteristic (AUROC) curve. The second level compared the magnitude of coefficients in logistic models in the two studies; while the third level tested whether the level of risk of CHD death in one sample could be estimated based on a risk function from the other sample. Result Coronary heart disease mortality was 515 per 100 000 person-years in Framingham and 311 per 100 000 person-years in Glostrup. The AUROC curve was between 75% and 77% and regardless of which risk-score was used. Logistic coefficients did not differ significantly between studies. The Framingham risk-score significantly overestimated the risk in the Glostrup sample and the Glostrup risk-score underestimated in the Framingham sample. Conclusion Using this Framingham risk-score on a Danish population will lead to a significant overestimation of coronary risk. The validity of risk-scores developed from populations with different incidence of the disease should preferably be tested prior to their application.
机译:背景技术由于在欧洲冠心病(CHD)发病率方面存在明显的地区差异,因此可以质疑欧洲心脏病学会根据弗雷明汉心脏病研究数据使用冠状动脉风险图的建议。方法使用来自两个总体研究的数据(Glstrup总体研究,n = 4757,Framingham心脏研究,n = 2562)来检验三种不同水平的交叉验证。第一级检查是使用接收者操作特征下的面积(AUROC)曲线,从一个样本中得出的风险评分是否足以对另一个样本中的参与者的风险进行排序。第二层比较了两项研究中逻辑模型中系数的大小;而第三级则测试是否可以根据另一样本的风险函数估算一个样本中冠心病死亡的风险水平。结果弗雷明汉的冠心病死亡率为每10万人年515例,格洛斯楚普每10万人年311例。无论使用哪种风险评分,AUROC曲线在75%至77%之间。在研究之间,逻辑系数没有显着差异。 Framingham风险评分明显高估了Glostrup样本中的风险,而Glostrup风险评分低估了Framingham样本中的风险。结论在丹麦人群中使用此Framingham风险评分将导致对冠心病风险的高估。从具有不同疾病发生率的人群获得的风险评分的有效性应优选在应用之前进行测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号